PubRank

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Clinical Trial ID NCT01688492

PubWeight™ 14.87‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01688492

Top papers

Rank Title Journal Year PubWeight™‹?›
1 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
2 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
3 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
4 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
5 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
6 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
7 Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 2013 0.85
8 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
9 Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol 2016 0.83
10 New drugs in prostate cancer. Prostate Int 2016 0.80
11 Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging 2014 0.80
12 Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther 2013 0.79
13 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015 0.77
14 Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016 0.76
15 Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016 0.75
16 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
17 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
Next 100